Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026